Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Suttajit, Sirijit; Arunpongpaisal, Suwanna; Srisurapanont, Manit; Thavichachart, Nuntika; Kongsakon, Ronnachai; Chantakarn, Sunanta; Chantarasak, Vasu; Jariyavilas, Apichat; Jaroensook, Piyadit; Kittiwattanagul, Khanogwan; Nerapusee, Osot

doi:10.2147/ndt.s88085

Cited by 22 publications

(13 citation statements)

References 44 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Negative symptoms are well established predictors of poor functional outcome in schizophrenia [84,94,95], this being true whether we consider impairments in socially useful activities, personal and social relationships, activities related to one's self-care [4] or decreased quality of life [96].…”

Section: Negative Symptoms and Psychosocial Functioningmentioning

confidence: 99%

“…Nonetheless, although functional recovery could be advocated as an achievable treatment goal, many effective interventions for the treatment of psychotic symptoms, such as antipsychotic drugs, may not improve functioning [4]. In this paper we will address the relative contribution of two key constructs-social cognitive deficits and negative symptoms, namely how intertwined they could be in daily life functioning of patients with schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Social Cognition, Negative Symptoms and Psychosocial Functioning in Schizophrenia

Madeira¹,

Caldeira²,

Bajouco³

et al. 2016

IJCNMH

View full text Add to dashboard Cite

Although functional recovery could be advocated as an achievable treatment goal, many effective interventions for the treatment of psychotic symptoms, such as antipsychotic drugs, may not improve functioning. The last two decades of cognitive and clinical research on schizophrenia were a turning point for the firm acknowledgment of how relevant social cognitive deficits and negative symptoms could be in predicting psychosocial functioning. The relevance of social cognition dysfunction in schizophrenia patients' daily living is now unabated. In fact, social cognition deficits could be the most significant predictor of functionality in patients with schizophrenia, non-redundantly with neurocognition. Emerging evidence suggests that negative symptoms appear to play an indirect role, mediating the relationship between neurocognition and social cognition with functional outcomes. Further explorations of this mediating role of negative symptoms have revealed that motivational deficits appear to be particularly important in explaining the relationship between both neurocognitive and social cognitive dysfunction and functional outcomes in schizophrenia. In this paper we will address the relative contribution of two key constructs-social cognitive deficits and negative symptoms, namely how intertwined they could be in daily life functioning of patients with schizophrenia.

show abstract

Section: Negative Symptoms and Psychosocial Functioningmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Social Cognition, Negative Symptoms and Psychosocial Functioning in Schizophrenia

Madeira¹,

Caldeira²,

Bajouco³

et al. 2016

IJCNMH

View full text Add to dashboard Cite

show abstract

“…Patients with higher Drug Attitude Inventory (DAI) scores respond more favorably to antipsychotics [12] and have better social functioning outcomes [13]. Psychotic symptoms are associated with a low level of social functioning [14]. Thus, changes in attitudes toward medication or changes in psychotic symptoms could be 2 of the factors affecting the link between insight and personal-social functions in patients with schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Psychotic Symptoms and Attitudes toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up

et al. 2018

View full text Add to dashboard Cite

Aims: This study aimed to investigate the mediating pathway of 3 factors (psychotic symptoms, attitude toward medication, and cognitive processing speed) on the effect of insight on personal-social functioning in patients with schizophrenia. Methods: Chinese inpatients with schizophrenia (n = 168; mean age 18 ± 50 years) diagnosed according to the DSM-IV were randomly assigned to treatment with antipsychotic medication alone or combined treatment. Positive and Negative Syndrome Scale (PANSS), Drug Attitude Inventory (DAI), Assessment of Insight (SAI), and Social-Personal Performance Scale (PSPS) scores were evaluated at baseline and at 3, 6, and 12 months. Cognitive function was assessed at baseline. Multiple mediation analyses were conducted with baseline data, end point data, and changes-in-scale scores between baseline and the end point, respectively. Results: At baseline and at 12 months, only psychotic symptoms mediated the effect of insight on personal-social functioning. For changes-in-scale scores over the 12-month follow-up, in patients receiving treatment with medication alone, the effect of improved insight on improved personal-social function was mediated by psychotic symptoms only; in patients receiving a combined treatment, the effect of improved insight on improved personal-social functioning was mediated by both psychotic symptoms and attitudes toward medication, independently. Conclusions: The link between insight and personal-social functions is mainly mediated by psychotic symptoms. Psychosocial intervention improves the predicting effect of insight on personal-social function by improving both the attitude toward medication and psychotic symptoms independently.

show abstract

“…The PERFEcT study was an open-label prospective trial to explore the tolerability, safety, and efficacy of flexibly dosed paliperidone ER in subjects with schizophrenia 11,12. Flexible dosing of paliperidone ER in a range of 3–12 mg/day was used, allowing investigators to adjust the dosage of each subject individually.…”

Section: Methodsmentioning

confidence: 99%

“…To investigate the efficacy of paliperidone ER in Southeast Asian patients with schizophrenia, the PERFEcT study was conducted from June 2007 to April 2009 11,12. Derived from the PERFEcT study, these findings describe the efficacy of paliperidone ER on hostility among Thai patients with schizophrenia who had switched from other antipsychotic medications because of lack of efficacy, poor tolerability, or poor compliance.…”

Section: Introductionmentioning

confidence: 99%

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Jariyavilas¹,

Thavichachart

Kongsakon

et al. 2017

NDT

Self Cite

View full text Add to dashboard Cite

ObjectiveThis open-label prospective study investigated the effects of paliperidone extended release (ER) on hostility in Thai patients with schizophrenia.BackgroundPatients diagnosed with schizophrenia may be hostile or exhibit aggressive behavior, which can occasion their admission to psychiatric hospital. Antipsychotic medications are often used to treat hostility and aggression in such patients. Paliperidone ER is effective and well tolerated in the treatment of schizophrenia. However, there are no data available for paliperidone ER with regard to its efficacy on hostility and aggression among Thai patients. This study was a part of the PERFEcT study, a 6-month, open-label, multicenter, multicountry, prospective trial to explore the safety, efficacy, and functionality of paliperidone ER tablets. The current study included only the data obtained from Thai participants.Materials and methodsFlexible dosing of paliperidone ER in a range of 3–12 mg/day was used, allowing investigators to adjust the dosage of each subject individually. The 199 Thai patients had a stable Clinical Global Impression – severity score before enrollment. Demographic data were collected at enrollment, and assessments took place at 1, 2, 3, and 6 months postbaseline. The Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) scale were used to evaluate efficacy. In this analysis, we report the findings for the specific PANSS factor P7 (hostility) and the PSP subscale disturbing and aggressive behavior. Data were analyzed using paired t-test method to investigate changes in mean PANSS and PSP total and subscale scores. The significance level was set at P<0.05.ResultsFrom a total of 199 Thai patients, 148 patients (74.4%) participated in all visits. There was a significant reduction in mean scores for all total PANSS measures from 1 month onward compared with baseline, as well as ongoing significant reductions in scores from visit to visit. There was a significant reduction in mean hostility score at 2 months (P<0.05), 3 months (P<0.05), and 6 months (P<0.01) (n=148). For the PSP scale, there was a significant across-the-board reduction of mean scores from 3 months onward, including in the disturbing and aggressive behavior subscale (P<0.001) (n=148).ConclusionSwitching from previously unsuccessful antipsychotic treatments to paliperidone ER may be a useful option to reduce hostility and disturbing behavior in patients with schizophrenia. This study in Thai patients is in line with findings in other countries and cultures concerning the management of hostility in patients with schizophrenia.

show abstract

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Cited by 22 publications

References 44 publications

Social Cognition, Negative Symptoms and Psychosocial Functioning in Schizophrenia

Social Cognition, Negative Symptoms and Psychosocial Functioning in Schizophrenia

Psychotic Symptoms and Attitudes toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Contact Info

Product

Resources

About